GKB202 suppresses endothelin-1/ERK signaling in pancreatic cancer cells: Potential implications for circulating tumor cell regulation

Affiliations

• 1 PhD Program for Health Science and Industry, China Medical University, Taichung, Taiwan.
• 2 Department of Pathology, Stanford University, Stanford, CA, USA; Department of Bioengineering, Stanford University, CA, USA.
• 3 Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
• 4 Biotech Research Institute, Grape King Bio Ltd., Taoyuan, Taiwan.
• 5 The Ph.D. Program of Biotechnology and Biomedical Industry, and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan; Department of Medical Laboratory and Biotechnology, Asia University, Taichung, Taiwan.
• 6 CancerFree Biotech Ltd., Taipei, Taiwan.
• 7 TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; International Ph. D. Program for Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan. Electronic address: lslu@tmu.edu.tw.
• 8 Biotech Research Institute, Grape King Bio Ltd., Taoyuan, Taiwan. Electronic address: tsungju.li@grapeking.com.tw.
• 9 Biotech Research Institute, Grape King Bio Ltd., Long Tan Dist., Taoyuan City 325, Taiwan; Institute of BioPharmaceutical Science, National Sun Yat-sen University, Kaohsiung 804, Taiwan; Institute of Food Science and Technology, National Taiwan University, Taipei 106, Taiwan. Electronic address: gkbioeng@grapeking.com.tw.